Sugi Predict

Sugi Predict / Compounds / SCHEMBL17064322

SCHEMBL17064322

SCHEMBL17064322

Nc1cc(C(O)c2ccncc2)ccc1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP17A1 P05093 3/20 0.47
▸ CYP11B1 P15538 2/20 0.47
▸ CYP11B2 P19099 2/20 0.47
▸ CYP19A1 P11511 2/20 0.47
▸ CYP3A4 P08684 2/20 0.47
▸ DPP4 P27487 2/20 0.38
▸ DPP8 Q6V1X1 1/20 0.36
▸ CHEK2 O96017 1/20 0.36
▸ LTA4H P09960 1/20 0.35
▸ CYP2C9 P11712 2/20 0.34
▸ CYP2C19 P33261 2/20 0.34
▸ AKR1C3 P42330 1/20 0.34
▸ AKR1C2 P52895 1/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ CYP2D6 P10635 1/20 0.34
▸ RAF1 P04049 1/20 0.34
▸ MAP4K4 O95819 1/20 0.33
▸ BRD4 O60885 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ NR3C1 P04150 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17064619 0.82 CA1 (0.41) CYP3A4CYP2D6SMN1; SMN2CA1CA2
SCHEMBL17064655 0.81 SMN1; SMN2 (0.56) CYP17A1CYP11B1CYP19A1AKR1C3AKR1C2
SCHEMBL29825564 0.81 DPP4 (0.42) CYP17A1CYP11B1CYP11B2CYP19A1CYP3A4
SCHEMBL17064481 0.81 DPP4 (0.42) CYP17A1CYP11B1CYP11B2CYP19A1CYP3A4
SCHEMBL18623110 0.78 KIF11 (0.35) SMN1; SMN2NR3C1CA1CA2CA9
SCHEMBL17064991 0.77 TOP2A (0.37) CYP19A1CYP3A4CYP1A2BRD4SMN1; SMN2
SCHEMBL17064634 0.77 AOC3 (0.41) CYP3A4CHEK2CYP2C19CYP1A2CYP2D6
SCHEMBL22417087 0.76 DPP4 (0.36) CYP17A1CYP19A1CYP3A4DPP4DPP8
SCHEMBL23882924 0.75 CYP19A1 (0.59) CYP17A1CYP11B1CYP11B2CYP19A1CYP3A4
SCHEMBL11196968 0.75 CYP19A1 (0.59) CYP17A1CYP11B1CYP11B2CYP19A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4663636-A2 TRIFLUOROMETHYL SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS BioCryst Pharmaceuticals, Inc. (US) 2025-12-17 — — EP disclosed
US-20250270171-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-08-28 — — US disclosed
US-20250257040-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-08-14 — — US disclosed
EP-4180424-B1 SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS BIOCRYST PHARM INC (US) 2025-06-25 — — EP disclosed
US-12162838-B2 Human plasma kallikrein inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2024-12-10 — — US disclosed
US-12116346-B2 Human plasma kallikrein inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2024-10-15 — — US disclosed
CN-113307772-B Human plasma kallikrein inhibitors 拜奥克里斯特制药公司 2024-06-28 — — CN disclosed
US-20240150296-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2024-05-09 — — US disclosed
US-20240150295-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2024-05-09 — — US disclosed
US-11708333-B2 Human plasma kallikrein inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2023-07-25 — — US disclosed
US-10329260-B2 Human plasma kallikrein inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2019-06-25 — — US disclosed
US-10329260-B2 Human plasma kallikrein inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2019-06-25 — — US disclosed
US-20180354906-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2018-12-13 — — US disclosed
US-10125102-B2 Human plasma kallikrein inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2018-11-13 — — US disclosed
US-20180258049-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2018-09-13 — — US disclosed
US-20170073314-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2017-03-16 — — US disclosed
US-20170073314-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2017-03-16 — — US disclosed
US-20170073314-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2017-03-16 — — US disclosed
EP-3113772-A1 HUMAN PLASMA KALLIKREIN INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2017-01-11 — — EP disclosed
WO-2015134998-A1 HUMAN PLASMA KALLIKREIN INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2015-09-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180354906-A1 HUMAN PLASMA KALLIKREIN INHIBITORS KLKB1, KLK1, KLK5 CYP17A1 245/4885CYP11B1 1724/4885CYP11B2 2006/4885
US-12116346-B2 Human plasma kallikrein inhibitors KLKB1, KLK5, KLK1 CYP17A1 165/4885CYP11B1 1165/4885CYP11B2 1524/4885
US-20250270171-A1 HUMAN PLASMA KALLIKREIN INHIBITORS KLKB1, KLK5, KLK1 CYP17A1 165/4885CYP11B1 1165/4885CYP11B2 1524/4885
US-20240150296-A1 HUMAN PLASMA KALLIKREIN INHIBITORS KLKB1, KLK5, KLK1 CYP17A1 165/4885CYP11B1 1165/4885CYP11B2 1524/4885
US-10329260-B2 Human plasma kallikrein inhibitors KLKB1, KLK1, KLK5 CYP17A1 245/4885CYP11B1 1724/4885CYP11B2 2006/4885
US-10125102-B2 Human plasma kallikrein inhibitors KLKB1, KLK1, KLK5 CYP17A1 245/4885CYP11B1 1724/4885CYP11B2 2006/4885
US-20170073314-A1 HUMAN PLASMA KALLIKREIN INHIBITORS KLKB1, KLK1, KLK5 CYP17A1 245/4885CYP11B1 1724/4885CYP11B2 2006/4885
US-20240150295-A1 HUMAN PLASMA KALLIKREIN INHIBITORS KLKB1, KLK5, KLK1 CYP17A1 165/4885CYP11B1 1165/4885CYP11B2 1524/4885
US-20250257040-A1 HUMAN PLASMA KALLIKREIN INHIBITORS KLKB1, KLK5, KLK1 CYP17A1 165/4885CYP11B1 1165/4885CYP11B2 1524/4885
US-11708333-B2 Human plasma kallikrein inhibitors KLKB1, KLK1, KLK5 CYP17A1 274/4885CYP11B1 1766/4885CYP11B2 2098/4885
US-20180258049-A1 HUMAN PLASMA KALLIKREIN INHIBITORS KLKB1, KLK1, KLK5 CYP17A1 245/4885CYP11B1 1724/4885CYP11B2 2006/4885
US-12162838-B2 Human plasma kallikrein inhibitors KLKB1, KLK5, KLK1 CYP17A1 165/4885CYP11B1 1165/4885CYP11B2 1524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.